Literature DB >> 11135287

Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. European Working Group on Clinical Cell Analysis.

B Brando1, D Barnett, G Janossy, F Mandy, B Autran, G Rothe, B Scarpati, G D'Avanzo, J L D'Hautcourt, R Lenkei, G Schmitz, A Kunkl, R Chianese, S Papa, J W Gratama.   

Abstract

The enumeration of absolute levels of cells and their subsets in clinical samples is of primary importance in human immunodeficiency virus (HIV)+ individuals (CD4+ T- lymphocyte enumeration), in patients who are candidates for autotransplantation (CD34+ hematopoietic progenitor cells), and in evaluating leukoreduced blood products (residual white blood cells). These measurements share a number of technical options, namely, single- or multiple-color cell staining and logical gating strategies. These can be accomplished using single- or dual-platform counting technologies employing cytometric methods. Dual-platform counting technologies couple the percentage of positive cell subsets obtained by cytometry and the absolute cell count obtained by automated hematology analyzers to derive the absolute value of such subsets. Despite having many conceptual and technical limitations, this approach is traditionally considered as the reference method for absolute cell count enumeration. As a result, the development of single-platform technologies has recently attracted attention with several different technical approaches now being readily available. These single-platform approaches have less sources of variability. A number of reports clearly demonstrate that they provide better coefficients of variation (CVs) in multicenter studies and a lower chance to generate aberrant results. These methods are therefore candidates for the new gold standard for absolute cell assessments. The currently available technical options are discussed in this review together with the results of some cross-comparative studies. Each analytical system has its own specific requirements as far as the dispensing precision steps are concerned. The importance of precision reverse pipetting is emphasized. Issues still under development include the establishment of the critical error ranges, which are different in each test setting, and the applicability of simplified low-cost techniques to be used in countries with limited resources.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11135287     DOI: 10.1002/1097-0320(20001215)42:6<327::aid-cyto1000>3.0.co;2-f

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  43 in total

1.  Affordable CD4(+)-T-cell counting by flow cytometry: CD45 gating for volumetric analysis.

Authors:  George Janossy; Ilesh V Jani; Nicholas J Bradley; Arsene Bikoue; Tim Pitfield; Debbie K Glencross
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

2.  Evaluation of a new single-parameter volumetric flow cytometer (CyFlow(green)) for enumeration of absolute CD4+ T lymphocytes in human immunodeficiency virus type 1-infected Thai patients.

Authors:  Kovit Pattanapanyasat; Surada Lerdwana; Egarit Noulsri; Thanyanan Chaowanachan; Punneeporn Wasinrapee; Natthaga Sakulploy; Vallerut Pobkeeree; Orapin Suksripanich; Sombat Thanprasertsuk; Thomas J Spira; Jordan W Tappero; William C Levine
Journal:  Clin Diagn Lab Immunol       Date:  2005-12

3.  ISHAGE-based single-platform flowcytometric analysis for measurement of absolute viable T cells in fresh or cryopreserved products: CD34/CD133 selected or CD3/CD19 depleted stem cells, DLI and purified CD56+CD3- NK cells.

Authors:  U Koehl; K Bochennek; R Esser; A Brinkmann; R Quaritsch; M Becker; J Soerensen; P Bader; D Schwabe; T Klingebiel; J Fischer; S Y Zimmermann
Journal:  Int J Hematol       Date:  2007-12-18       Impact factor: 2.490

4.  Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis.

Authors:  E Rodríguez-Martín; C Picón; L Costa-Frossard; R Alenda; S Sainz de la Maza; E Roldán; M Espiño; L M Villar; J C Álvarez-Cermeño
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

5.  Enumeration of major peripheral blood leukocyte populations for multicenter clinical trials using a whole blood phenotyping assay.

Authors:  Tiffany R Hensley; Austin B Easter; Sarah E Gerdts; Stephen C De Rosa; Antje Heit; M Juliana McElrath; Erica Andersen-Nissen
Journal:  J Vis Exp       Date:  2012-09-16       Impact factor: 1.355

6.  Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model.

Authors:  Chris J Weir; Amanda L Hudson; Lyndsay Peters; Viive M Howell
Journal:  J Vis Exp       Date:  2015-10-02       Impact factor: 1.355

7.  Optimized protocols for isolation, fixation, and flow cytometric characterization of leukocytes in ischemic hearts.

Authors:  Roman Covarrubias; Mohamed Ameen Ismahil; Gregg Rokosh; Tariq Hamid; Federica Accornero; Harpreet Singh; Richard J Gumina; Sumanth D Prabhu; Shyam S Bansal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-02       Impact factor: 4.733

8.  Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors.

Authors:  Maria Antonietta Avanzini; Maria Ester Bernardo; Angela Maria Cometa; Cesare Perotti; Nadia Zaffaroni; Francesca Novara; Livia Visai; Antonia Moretta; Claudia Del Fante; Raffaella Villa; Lynne M Ball; Willem E Fibbe; Rita Maccario; Franco Locatelli
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

9.  Low CD4+ T-lymphocyte values in human immunodeficiency virus-negative adults in Botswana.

Authors:  Hermann Bussmann; C William Wester; Kereng V Masupu; Trevor Peter; Sarah M Gaolekwe; Soyeon Kim; Ann Marie Reich; Sam Ahn; Ying Wu; Ibou Thior; Max Essex; Richard Marlink
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

10.  Surface markers of lymphocyte activation in pregnant asthmatics.

Authors:  Anikó Bohács; Eva Pállinger; Lilla Tamási; János Rigó; Zsolt Komlósi; Veronika Müller; Yang Dong; Pál Magyar; András Falus; György Losonczy
Journal:  Inflamm Res       Date:  2010-01       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.